SG10202000590SA - Antimitotic amides for the treatment of cancer and proliferative disorders - Google Patents

Antimitotic amides for the treatment of cancer and proliferative disorders

Info

Publication number
SG10202000590SA
SG10202000590SA SG10202000590SA SG10202000590SA SG10202000590SA SG 10202000590S A SG10202000590S A SG 10202000590SA SG 10202000590S A SG10202000590S A SG 10202000590SA SG 10202000590S A SG10202000590S A SG 10202000590SA SG 10202000590S A SG10202000590S A SG 10202000590SA
Authority
SG
Singapore
Prior art keywords
antimitotic
amides
cancer
treatment
proliferative disorders
Prior art date
Application number
SG10202000590SA
Inventor
Adam Siddiqui-Jain
Original Assignee
Frost Biologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frost Biologic Inc filed Critical Frost Biologic Inc
Publication of SG10202000590SA publication Critical patent/SG10202000590SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
SG10202000590SA 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders SG10202000590SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461942956P 2014-02-21 2014-02-21

Publications (1)

Publication Number Publication Date
SG10202000590SA true SG10202000590SA (en) 2020-03-30

Family

ID=52684675

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201606869TA SG11201606869TA (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders
SG10202000590SA SG10202000590SA (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201606869TA SG11201606869TA (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders

Country Status (14)

Country Link
US (4) US10016398B2 (en)
EP (1) EP3107909B1 (en)
JP (1) JP6506313B2 (en)
KR (1) KR102420508B1 (en)
CN (2) CN114634483B (en)
AU (1) AU2015218775C1 (en)
BR (1) BR112016019161B1 (en)
CA (1) CA2940237C (en)
ES (1) ES2893374T3 (en)
IL (1) IL247293B (en)
MX (1) MX2016010877A (en)
RU (1) RU2713179C2 (en)
SG (2) SG11201606869TA (en)
WO (1) WO2015127284A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420622B1 (en) 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
BR112016019161B1 (en) * 2014-02-21 2022-12-20 Frost Biologic, Inc ANTIMITOTIC AMIDES, PHARMACEUTICAL COMPOSITIONS INCLUDING THEM AND THEIR USE
CN106727583A (en) * 2016-12-12 2017-05-31 范旭升 A kind of pharmaceutical composition for treating diastolic heart failure
WO2019014460A1 (en) * 2017-07-12 2019-01-17 The Brigham And Women's Hospital, Inc. Eaat2 enhancing molecules
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
NZ522990A (en) * 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
WO2006002896A1 (en) * 2004-06-30 2006-01-12 Novartis Ag Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors
WO2007018319A1 (en) * 2005-08-11 2007-02-15 Takeda Pharmaceutical Company Limited Pyridylphenol compound and use thereof
WO2007089904A2 (en) * 2006-01-31 2007-08-09 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
US20090274655A1 (en) 2006-11-17 2009-11-05 Richard Martin Grimes 2-carboxy thiophene derivatives as anti viral agents
CA2683624A1 (en) * 2007-04-12 2008-10-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
TW201018666A (en) * 2008-10-01 2010-05-16 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
HUE024568T2 (en) * 2009-09-11 2016-02-29 Amgen Inc N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
DK2563776T3 (en) * 2010-04-27 2016-09-19 Calcimedica Inc Relations that modulate intracellular calcium
WO2011142151A1 (en) * 2010-05-14 2011-11-17 シャープ株式会社 Portable information terminal and method for controlling same
TWI541243B (en) * 2010-09-10 2016-07-11 拜耳知識產權公司 Substituted imidazopyridazines
CA2824544A1 (en) * 2011-01-21 2012-07-26 Anil Vasudevan Picolinamide inhibitors of kinases
US8748432B2 (en) * 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
CA2834928C (en) * 2011-05-03 2017-10-17 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
JP2014532656A (en) * 2011-10-28 2014-12-08 シンタ ファーマシューティカルズ コーポレーション Compounds for inflammation and immune related applications
BR112016019161B1 (en) * 2014-02-21 2022-12-20 Frost Biologic, Inc ANTIMITOTIC AMIDES, PHARMACEUTICAL COMPOSITIONS INCLUDING THEM AND THEIR USE

Also Published As

Publication number Publication date
US20220008395A1 (en) 2022-01-13
US20200397758A1 (en) 2020-12-24
RU2016135555A3 (en) 2018-10-05
US11129813B2 (en) 2021-09-28
WO2015127284A3 (en) 2015-10-15
US10016398B2 (en) 2018-07-10
IL247293B (en) 2021-01-31
ES2893374T3 (en) 2022-02-08
CA2940237C (en) 2023-03-07
RU2016135555A (en) 2018-03-28
EP3107909A2 (en) 2016-12-28
WO2015127284A2 (en) 2015-08-27
JP2017506267A (en) 2017-03-02
KR20160116009A (en) 2016-10-06
US20170172984A1 (en) 2017-06-22
CA2940237A1 (en) 2015-08-27
US10772872B2 (en) 2020-09-15
CN114634483B (en) 2024-08-13
BR112016019161B1 (en) 2022-12-20
KR102420508B1 (en) 2022-07-13
US20180325871A1 (en) 2018-11-15
CN114634483A (en) 2022-06-17
EP3107909B1 (en) 2021-07-14
BR112016019161A2 (en) 2017-08-15
AU2015218775B2 (en) 2019-06-20
CN106068263A (en) 2016-11-02
AU2015218775C1 (en) 2020-01-16
MX2016010877A (en) 2017-05-04
IL247293A0 (en) 2016-09-29
JP6506313B2 (en) 2019-04-24
AU2015218775A1 (en) 2016-08-25
SG11201606869TA (en) 2016-09-29
RU2713179C2 (en) 2020-02-04

Similar Documents

Publication Publication Date Title
IL262416A (en) Materials and methods for treatment of hemoglobinopathies
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
SG11201706766WA (en) Materials and methods for treatment of hemoglobinopathies
SG11201703193XA (en) Treatment for depression and depressive disorders
GB201405232D0 (en) Apparatus and methods for the treatment of ocular disorders
HRP20190888T8 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
PL3122358T3 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
EP3157336A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
GB201506851D0 (en) Apparatus and method for providing hyperthermia therapy
IL251904A0 (en) Apilimod for use in the treatment of melanoma
IL247293B (en) Antimitotic amides for the treatment of cancer and proliferative disorders
EP3154616A4 (en) Methods and apparatus for treatment of respiratory disorders
EP3302207A4 (en) Surface treatment apparatuses and methods
EP4043567C0 (en) Methods and compositions for the treatment of cancer
HK1245778A1 (en) Small molecules for the treatment of primary cancer and cancer metastasis
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
AU2016905121A0 (en) Methods of Treating Proliferative Disorders
PL3190212T3 (en) Apparatus for the surface treatment of a continuous material and its use
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201414904D0 (en) Materials and methods for treating cancer